EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy

Emiel Leegwater, Lauren Baidjoe, Erik B Wilms iD, Leo G Visser, Daniel J Touw iD, Brenda C M de Winter iD, Mark G J de Boer, Judith van Paassen iD, Charlotte H S B van den Berg, Joffrey van Prehn iD, Teun van Gelder iD, Dirk Jan A R Moes iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3421 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Emiel Leegwater und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands. Hauptthemen laut MEDLINE: Trimethoprim, Sulfamethoxazole Drug Combination, Renal Insufficiency, Pneumonia, Pneumocystis, Continuous Renal Replacement Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The goal of the study was to describe the population pharmacokinetics of trimethoprim, sulfamethoxazole, and N ‐acetyl sulfamethoxazole in hospitalized patients. Furthermore, this study used the model to optimize dosing regimens of cotrimoxazole for Pneumocystis jirovecii pneumonia and in patients with renal insufficiency or with continuous renal replacement therapy (CRRT). This was a retrospective multicenter observational cohort study based on therapeutic drug monitoring (TDM) data from hospitalized patients treated with cotrimoxazole. We developed two population pharmacokinetic (POPPK) models: a model of trimethoprim and an integrated model with both sulfamethoxazole and N ‐acetyl sulfamethoxazole concentrations. Monte Carlo simulations were performed to determine the optimal dosing regimen. A total of 348 measurements from 168 patients were available. The estimated glomerular filtration rate (eGFR) and CRRT were included as covariates on the clearance of all three compounds. Cotrimoxazole TID 1,920 mg and b.i.d. 2,400 mg led to sufficient exposure for infections with P. jirovecii in patients without renal insufficiency. To reach equivalent exposure, a dose reduction of 33.3% is needed in patients with an eGFR of 10 mL/minute/1.73 m 2 and of 16.7% for an eGFR of 30 mL/minute/1.73 m 2 . N ‐acetyl sulfamethoxazole accumulates in patients with a reduced eGFR. CRRT increased the clearance of sulfamethoxazole, but not trimethoprim or N ‐acetyl sulfamethoxazole, compared with the median clearance in the population. Doubling the sulfamethoxazole dose is needed for patients on CRRT to reach equivalent exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trimethoprim, Sulfamethoxazole Drug CombinationRenal InsufficiencyPneumonia, PneumocystisContinuous Renal Replacement TherapyDrug MonitoringHumansMaleFemaleRetrospective StudiesMiddle AgedAgedMonte Carlo MethodGlomerular Filtration RateAdultModels, BiologicalAged, 80 and overCohort StudiesDose-Response Relationship, Drug

Substanzen

Trimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands.
  • Apotheek Haagse Ziekenhuizen, The Hague, The Netherlands.
  • Department of Infectious Diseases, Leiden University Center for Infectious Diseases (LU-CID) Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Erik B Wilms, Daniel J Touw, Brenda C M de Winter, Judith van Paassen, Joffrey van Prehn, Teun van Gelder, Dirk Jan A R Moes

Zitieren

APA

Leegwater, E., Baidjoe, L., Wilms, E. B., Visser, L. G., Touw, D. J., de Winter, B. C. M., de Boer, M. G. J., van Paassen, J., van den Berg, C. H. S. B., van Prehn, J., van Gelder, T., & Moes, D. J. A. R. (2025). Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3421

Vancouver

Leegwater E, Baidjoe L, Wilms EB, Visser LG, Touw DJ, de Winter BCM, et al. Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3421

BibTeX
@article{Leegwater2025,
  author = {Leegwater, Emiel and Baidjoe, Lauren and Wilms, Erik B and Visser, Leo G and Touw, Daniel J and de Winter, Brenda C M and de Boer, Mark G J and van Paassen, Judith and van den Berg, Charlotte H S B and van Prehn, Joffrey and van Gelder, Teun and Moes, Dirk Jan A R},
  title = {Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3421}
}
Kostenlos starten →